Vistagen Therapeutics Inc
VTGN4.020USD
-0.160-3.83%
收盘 11/06, 16:00（美东）报价延迟15分钟
117.71M总市值
亏损市盈率 TTM
关于 Vistagen Therapeutics Inc 公司
Vistagen Therapeutics, Inc. 是一家专注于神经科学的生物制药公司。该公司基于对鼻脑神经回路的理解，致力于开发和商业化治疗精神和神经疾病的疗法。其临床阶段产品线包括一种新型潜在神经科学疗法（称为 pherines）的鼻内产品候选物。其多样化的 pherine 产品候选物产品线可快速激活鼻腔中的化学感应神经元，从而影响嗅觉系统和大脑中的基本神经回路。其产品线还包括一种口服前药，具有调节 N-甲基-D-天冬氨酸受体 (NMDA) 受体活性的潜力。其神经科学产品线包括五种临床阶段研究药物，即 Fasedienol (PH94B)、Itruvone (PH10)、AV-101、PH15、PH80 和 PH284。
Vistagen Therapeutics Inc简介
公司代码VTGN
公司名称Vistagen Therapeutics Inc
上市日期Oct 18, 2010
CEOMr. Shawn K. Singh, J.D.
员工数量56
证券类型Ordinary Share
年结日Oct 18
公司地址343 Allerton Avenue
城市SOUTH SAN FRANCISCO
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编94080
电话16505773600
网址https://www.vistagen.com/
公司代码VTGN
上市日期Oct 18, 2010
CEOMr. Shawn K. Singh, J.D.
Vistagen Therapeutics Inc公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Shawn K. Singh, J.D.
Mr. Shawn K. Singh, J.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
38.90K
--
Mr. Joshua S Prince
Mr. Joshua S Prince
Chief Operating Officer
Chief Operating Officer
10.86K
--
Mr. Jon S. Saxe, J.D.
Mr. Jon S. Saxe, J.D.
Independent Director
Independent Director
1.86K
--
Mr. Reid G. Adler, J.D.
Mr. Reid G. Adler, J.D.
Chief Legal Officer
Chief Legal Officer
--
--
Ms. Margaret M. (Maggie) Fitzpatrick
Ms. Margaret M. (Maggie) Fitzpatrick
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Mary L. Rotunno
Ms. Mary L. Rotunno
Independent Director
Independent Director
--
--
Dr. Joanne Curley, Ph.D.
Dr. Joanne Curley, Ph.D.
Independent Director
Independent Director
--
--
Ms. Elissa Cote
Ms. Elissa Cote
Chief Corporate Development Officer
Chief Corporate Development Officer
--
--
Ms. Ann Michelle Cunningham
Ms. Ann Michelle Cunningham
Non-Executive Non-Independent Director
Non-Executive Non-Independent Director
--
--
Mr. Mark A. Mcpartland
Mr. Mark A. Mcpartland
Senior Vice President - Investor Relations
Senior Vice President - Investor Relations
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Shawn K. Singh, J.D.
Mr. Shawn K. Singh, J.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
38.90K
--
Mr. Joshua S Prince
Mr. Joshua S Prince
Chief Operating Officer
Chief Operating Officer
10.86K
--
Mr. Jon S. Saxe, J.D.
Mr. Jon S. Saxe, J.D.
Independent Director
Independent Director
1.86K
--
Mr. Reid G. Adler, J.D.
Mr. Reid G. Adler, J.D.
Chief Legal Officer
Chief Legal Officer
--
--
Ms. Margaret M. (Maggie) Fitzpatrick
Ms. Margaret M. (Maggie) Fitzpatrick
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Mary L. Rotunno
Ms. Mary L. Rotunno
Independent Director
Independent Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 9月13日 周六
更新时间: 9月13日 周六
持股股东
股东类型
持股股东
持股股东
占比
Janus Henderson Investors
13.95%
TCG Crossover Management, LLC
8.96%
Nantahala Capital Management, LLC
6.63%
StemPoint Capital LP
6.02%
The Vanguard Group, Inc.
5.65%
其他
58.79%
持股股东
持股股东
占比
Janus Henderson Investors
13.95%
TCG Crossover Management, LLC
8.96%
Nantahala Capital Management, LLC
6.63%
StemPoint Capital LP
6.02%
The Vanguard Group, Inc.
5.65%
其他
58.79%
股东类型
持股股东
占比
Investment Advisor
25.24%
Hedge Fund
19.02%
Investment Advisor/Hedge Fund
16.23%
Research Firm
3.38%
Individual Investor
0.34%
其他
35.79%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
105
19.07M
63.87%
-1.31M
2025Q2
119
15.55M
52.09%
-4.48M
2025Q1
178
15.52M
53.23%
-4.54M
2024Q4
189
15.27M
53.10%
-1.38M
2024Q3
188
15.00M
55.60%
-3.08M
2024Q2
215
16.08M
59.60%
-5.25M
2024Q1
231
17.00M
63.09%
-4.65M
2023Q4
242
17.28M
64.17%
+1.95M
2023Q3
236
3.11M
33.43%
-2.83M
2023Q2
238
1.09M
13.89%
-3.94M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Janus Henderson Investors
4.17M
13.95%
+4.17M
--
Aug 29, 2025
TCG Crossover Management, LLC
2.68M
8.96%
--
--
Jun 30, 2025
Nantahala Capital Management, LLC
1.98M
6.63%
--
--
Jun 30, 2025
StemPoint Capital LP
1.80M
6.02%
+46.70K
+2.67%
Jun 30, 2025
The Vanguard Group, Inc.
1.76M
5.89%
-200.53K
-10.23%
Jun 30, 2025
Commodore Capital LP
1.57M
5.27%
--
--
Jun 30, 2025
J.P. Morgan Securities LLC
748.85K
2.51%
-2.01K
-0.27%
Jun 30, 2025
Ikarian Capital LLC
601.70K
2.02%
--
--
Jun 30, 2025
Sphera Funds Management Ltd.
447.94K
1.5%
-342.61K
-43.34%
Jun 30, 2025
Adar1 Capital Management LLC
420.76K
1.41%
--
--
Jun 30, 2025
查看更多
持股ETF
更新时间: 13 小时前
更新时间: 13 小时前
机构名称
占比
AdvisorShares Psychedelics ETF
5.35%
iShares Micro-Cap ETF
0.02%
Avantis US Small Cap Equity ETF
0.01%
iShares Neuroscience and Healthcare ETF
0%
AdvisorShares Psychedelics ETF
占比5.35%
iShares Micro-Cap ETF
占比0.02%
Avantis US Small Cap Equity ETF
占比0.01%
iShares Neuroscience and Healthcare ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Jun 06, 2023
Merger
30→1
Jun 06, 2023
Merger
30→1
Jun 06, 2023
Merger
30→1
Jun 06, 2023
Merger
30→1
公告日期
类型
比率
Jun 06, 2023
Merger
30→1
Jun 06, 2023
Merger
30→1
Jun 06, 2023
Merger
30→1
Jun 06, 2023
Merger
30→1
